Manipal Health Enterprises Ltd. Share Price

Manipal Hospitals Repays ₹5,310 Crore NCDs

Research Analyst: UJVIN NEVATIA (PROPRIETOR: NEVAT INVESTMENTS) | SEBI Registration No.: INH100009628 Manipal Health Enterprises Limited (

), which operates Manipal Hospitals, has fully redeemed ₹5,310 crore of NCDs issued by its wholly owned subsidiary using part of its IPO proceeds. The repayment included principal, accrued interest and applicable prepayment costs. What happened? The NCDs were originally issued in September 2025 at a 9.03% annual coupon and had a two-year tenure. The IPO prospectus had identified repayment of this acquisition-linked debt as one of the uses of the fresh issue proceeds. Why does it matter? This is more than a routine debt repayment. Manipal had used the NCDs to fund its expansion, including the acquisition of Sahyadri Hospitals. Redeeming them now changes the funding structure created by that expansion. My view The key benefit is the removal of a relatively high-cost debt obligation. At a 9.03% coupon, ₹5,310 crore of principal represented a gross annual coupon outflow of roughly ₹480 crore, before considering the actual repayment timing and accrued interest. The improvement in leverage will matter more if the company can retain the earnings generated by its expanded hospital network while reducing financing costs. What I am watching next The key metrics are interest expense, net debt, EBITDA and cash generation in the coming quarters. These will show whether the IPO-funded deleveraging is translating into a sustained improvement in the balance sheet rather than simply replacing one source of funding with another. No Recommendations Source: NDTV Profit Disclosure: I, my entity, associates or relatives don't have any holding, position or other material interest in Manipal Health Enterprises Limited.

See More

Manipal Health Enterprises Initiations & Valuation Outlook

Shares of newly listed Manipal Health Enterprises gained nearly 3% intraday before consolidating near ₹739.45 (+1.3% from the previous close of ₹729.95) following a flurry of coverage initiations by global brokerages. Street sentiment remains tilted positive with an overarching debate centered on operational execution versus rich entry valuations. Across seven tracked sell-side analysts, consensus stands at 4 "Buy" and 3 "Hold" ratings, with zero "Sell" recommendations. Target prices range between ₹800 and ₹870, implying an upside of 9.6% to 19.2%. Brokerage Stance Target Price Implied Upside Core Rationale Jefferies Buy ₹870 +19.2% Street-high target; strong sector tailwinds and scale advantages. Goldman Sachs Buy ₹865 +18.5% Projected >20% revenue CAGR (FY26–29); operating leverage expansion beyond FY26 base EBITDA margin of 26.3% (ex-Sahyadri). UBS Neutral ₹850 +16.4% Robust 19% revenue / 20% EBITDA CAGR (FY26–30), offset by 28x 1-year forward EV/EBITDA vs. peer average of 24x. JPMorgan Neutral ₹800 +9.6% Steady ARPOB and +2,600 bed expansion by FY30, weighed down by high-single-digit return ratios and Sahyadri integration lag. Key Investment Theses & Headwinds Topline Visibility & Margin Expansion: Bulls emphasize top-quartile revenue growth driven by bed capacity ramp-ups and a proven track record of integrating M&A assets (over 5,500 beds acquired over the past 5–6 years). Operating leverage is expected to widen core EBITDA margins over the medium term. Valuation & Return Ratio Constraints: Cautious analysts argue that growth is largely priced into current multiples (trading at 27x/22x FY28/29 EV/EBITDA). M&A-heavy capital deployment has depressed near-term Return on Invested Capital (ROIC) to high single digits, leaving re-rating dependent on swift turnaround execution at Sahyadri.

See More

Healthcare Facilities company Manipal Hospitals

Revenue from Operations for Q1FY27 was Rs 3,090.63 crore, showing a robust YoY growth of 38.12% from Rs 2,237.63 crore in Q1FY26 and a QoQ increase of 7.23% from Rs 2,882.35 crore in Q4FY26. Total Income stood at Rs 3,165.19 crore in Q1FY27, marking a YoY increase of 38.46% from Rs 2,285.98 crore in Q1FY26 and an 8.48% growth QoQ from Rs 2,917.85 crore in Q4FY26. Other Income for the quarter was reported at Rs 74.56 crore, up YoY from Rs 48.35 crore in Q1FY26. Profit before exceptional items and tax for Q1FY27 was Rs 330.65 crore, a decrease of 8.81% YoY from Rs 362.59 crore in Q1FY26, but a growth of 30.82% QoQ from Rs 252.75 crore in Q4FY26. Net Profit for the quarter stood at Rs 243.43 crore in Q1FY27, a YoY decline of 4.18% from Rs 254.04 crore in Q1FY26, and a QoQ increase of 30.50% from Rs 186.53 crore in Q4FY26. Total Comprehensive Income for the period was Rs 243.99 crore in Q1FY27, compared to Rs 252.92 crore in Q1FY26.

See More

Manipal Health Enterprises Ltd. (Results)

Q1FY27 Quarterly Result Announced for Manipal Health Enterprises Ltd.

Healthcare Facilities company Manipal Health Enterprises announced Q1FY27 results Standalone Financial Highlights: Revenue from Operations for Q1FY27 stood at Rs 1,048.30 crore, representing a YoY increase of 28.15% from Rs 818.02 crore in Q1FY26 and a QoQ growth of 8.42% from Rs 966.93 crore in Q4FY26. Total Income reached Rs 1,089.17 crore in Q1FY27, reflecting a YoY growth of 27.76% compared to Rs 852.54 crore in Q1FY26 and a QoQ increase of 9.68% from Rs 993.03 crore in Q4FY26. Other Income was reported at Rs 40.87 crore in Q1FY27, compared to Rs 34.52 crore in Q1FY26 and Rs 26.10 crore in Q4FY26. Profit before exceptional items and tax for the quarter was Rs 165.19 crore, a slight YoY decline of 1.68% from Rs 168.01 crore in Q1FY26, but a significant QoQ growth of 27.86% from Rs 129.20 crore in Q4FY26. The company recorded an Exceptional Item loss of Rs 13.43 crore in Q1FY27, primarily relating to provisions for the impact of new labour codes and discretionary one-time incentives. Net Profit for Q1FY27 stood at Rs 115.53 crore, representing a YoY decrease of 8.26% from Rs 125.93 crore in Q1FY26, while increasing 25.55% QoQ from Rs 92.02 crore in Q4FY26. Basic and Diluted Earnings Per Share (EPS) for Q1FY27 was Rs 0.98, compared to Rs 1.09 in Q1FY26 and Rs 0.79 in Q4FY26. All this is for information. This is not a buy/sell recommendation. Thank you, Technofunda24

See More

Manipal Health Enterprises – Q1 FY27

reported a strong Q1 FY27 performance, with revenue rising 38.1% YoY to ₹3,091 crore, while EBITDA increased 26.4% YoY to ₹749 crore. The results indicate continued strength in patient volumes, occupancy and demand for complex/specialty healthcare services. Reuters also reported that adjusted profit after tax rose nearly 31% YoY to ₹332 crore, supported by higher demand for complex procedures and improved hospital occupancy. Key financial highlights * Revenue: ₹3,091 crore, up 38.1% YoY. * EBITDA: ₹749 crore, up 26.4% YoY. * EBITDA margin: ~24.2%, versus roughly 26.5% in the year-ago period based on the reported growth rates. This suggests revenue growth was stronger than EBITDA growth, indicating some moderation in operating leverage. * Adjusted PAT: ~₹332 crore, up nearly 31% YoY. Operational performance remains the key driver: Manipal’s growth is being supported by rising patient throughput and increasing demand for high-value procedures. Its business has a significant presence across cardiac sciences, oncology, neurosciences, gastro sciences, orthopaedics and renal sciences. In FY26, these specialty areas together accounted for a substantial portion of revenue, with cardiac sciences being the largest specialty at around 16.8% of revenue. Capacity expansion provides a medium-term growth runway: The company operated 49 hospitals with 13,037 licensed beds in FY26, with about 6,878 operational beds. It has announced plans to invest around ₹4,000 crore to add 2,400 beds over the next 3–4 years, equivalent to an ~18% increase in its licensed-bed capacity. This should support revenue growth beyond the existing network as new facilities ramp up.

See More